Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01085474|
Recruitment Status : Completed
First Posted : March 12, 2010
Last Update Posted : January 28, 2013
|Condition or disease||Intervention/treatment|
|Asthma||Other: 1 Other: 2|
|Study Type :||Observational|
|Actual Enrollment :||384 participants|
|Official Title:||Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||July 2011|
|Actual Study Completion Date :||July 2011|
1. Pilot Study: 60 patients (all in the intervention group) 30 patients with intervention A and 30 patients with B intervention)
In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.
Main Study: 600 patients (30 pharmacies control group and 30 pharmacies intervention group, 10 patients per pharmacy)
The best intervention used in the pilot study will be chosen and included in the main study.
- Evaluate the effect of the pharmaceutical intervention on the disease control, treatment adherence and patient knowledge of his/her medication using the MEF, treatment adherence and patient knowledge of the medication indicators. [ Time Frame: First a Pilot in 3 months and then the final study in 6 months ]
- Compare disease control in patients who know their medication and those who doesn't. [ Time Frame: First a Pilot in 3 months and then the final study in 6 months ]
- Compare disease control in patients who comply with their medication with those who doesn't. [ Time Frame: First a Pilot in 3 months and then the final study in 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01085474